The U.S. Food and Drug Administration has rejected a pioneering lung cancer drug developed in China, marking a significant setback for Beijing's ambitions in the global biotechnology sector.
The US FDA has shelved its commissioner's priority review voucher pilot program for expedited drug reviews, according to exclusive reporting from Reuters and coverage across multiple outlets.